Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05166356 · ClinicalTrials.gov registry record
Determinants and Effects in the Use of NOHARM Pain Management
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 372
- Enrollment target
NCT05166356: Completed study, sponsored by Mayo Clinic.
NCT05166356 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 372 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05166356 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 372 participants
- Enrollment target
Study Summary
The objective of this study is to enrich the ongoing Non-pharmacological Pain Management After Surgery (NOHARM) pragmatic trial (NCT04570371) with a mixed methods analysis of patient and care team factors that affect the routine adoption, implementation, and meaningful and sustainable use of the NOHARM intervention.
Primary Outcome
Characteristics of high and low fidelity users of the intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2024-02-01 |
What the finished NCT05166356 record still lists
NCT05166356 is an observational study that tracks outcomes without assigning an intervention. The registered 372 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05166356 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05166356 about?
NCT05166356 is a clinical study titled "Determinants and Effects in the Use of NOHARM Pain Management". The objective of this study is to enrich the ongoing Non-pharmacological Pain Management After Surgery (NOHARM) pragmatic trial (NCT04570371) with a mixed methods analysis of patient and care team factors that affect the routine adoption, implementation, and meaningful and sustainable use of the NOH...
What is the current status of trial NCT05166356?
This trial is currently completed. The enrollment target is 372 participants. The study started on 2022-03-01. Estimated completion is 2024-02-01.
Who is sponsoring clinical trial NCT05166356?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- NCT06797635 · 372 participants · Phase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI